BRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002

Reuters

Feb 11

BRIEF-Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces First Patient Dosed In Phase 1 Study Of Stk-002

Feb 11 (Reuters) - Stoke Therapeutics Inc STOK.O:

STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF STK-002, A POTENTIAL DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)
STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTS

Source text: ID:nBw993Jrra

Further company coverage: STOK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610937612"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610937612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610937612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610937612","market":"us","top_or_hot":-1,"title":"BRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces First Patient Dosed In Phase 1 Study Of Stk-002</title></head><body><p><span>Feb 11 (Reuters)</span><span> - </span>Stoke Therapeutics Inc <span>STOK.O</span>:</p><ul><li><p>STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF STK-002, A POTENTIAL DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)</p></li><li><p>STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTS</p></li></ul><p>Source text: <span>ID:nBw993Jrra</span></p><p>Further company coverage: <span>STOK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 20:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces First Patient Dosed In Phase 1 Study Of Stk-002</title></head><body><p><span>Feb 11 (Reuters)</span><span> - </span>Stoke Therapeutics Inc <span>STOK.O</span>:</p><ul><li><p>STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF STK-002, A POTENTIAL DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)</p></li><li><p>STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTS</p></li></ul><p>Source text: <span>ID:nBw993Jrra</span></p><p>Further company coverage: <span>STOK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STOK","symbol_name":"Stoke Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA6YHZLR:1","article_id":"2610937612","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610937612","pubTimestamp":1770813997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002Feb 11 (Reuters) - Stoke Therapeutics Inc STOK.O:STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STOK":"Stoke Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Stoke Therapeutics宣布STK-002 1期研究中首例患者接受给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":0.9},"content_text":"BRIEF-Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002Feb 11 (Reuters) - Stoke Therapeutics Inc STOK.O:STOKE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF STK-002, A POTENTIAL DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)STOKE THERAPEUTICS INC: DOSE ESCALATION OF FIRST FOUR COHORTS WILL CONTINUE THROUGH 2026 AND EARLY 2027, PENDING SAFETY AND TOLERABILITY ASSESSMENTSSource text: ID:nBw993JrraFurther company coverage: STOK.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}